Pharmaceuticals

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

Canadian innovator Stealth Health enters the U.S. with a dual-model telemedicine platform for longevity, targeting both patients and healthcare providers.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

The conglomerate's massive impairment signals a strategic pivot to shed legacy assets and double down on its high-growth core businesses in pharma and tourism.

A new partnership aims to revolutionize fragile supply chains with AI, promising greater resilience, less waste, and enhanced safety for critical goods.

With promising early data and a unique brain delivery method, AviadoBio's AVB-101 trial offers new hope for patients with FTD-GRN, a devastating disease.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

A startling new study reveals a sharp rise in diagnosed anxiety, highlighting a growing public health crisis and an urgent need for treatment innovation.

After a successful shift to a royalty model, the firm reports stronger financials and confirms it is weighing a merger or acquisition.

Sangamo pushes a promising Fabry disease therapy toward the FDA while a cash crunch forces a strategic pivot to brain-targeting neurological cures.

NASDAQ-listed Bio Green Med Solution abandons its biopharma roots for fire safety, slashing losses but facing new questions about its long-term survival.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

The new DSP leverages 100% first-party HCP data, script-lift measurement, and sustainability metrics to offer unparalleled precision and performance.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.

Danish firm Evaxion, backed by the Gates Foundation, uses its AI platform to design a next-gen polio vaccine, aiming to end the disease for good.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

Tenpoint Therapeutics launches YUVEZZI, a once-daily drop for presbyopia, entering a fierce market with a novel two-in-one formula for aging eyes.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.